Dear Colleagues,

The microenvironment plays an important role in tumorigenesis and development. Multiple tumor microenvironments promote tumor growth and induce immune tolerance, including tumor angiogenesis, tumor-associated macrophage (TAM) and T cell immunosuppression, etc. It is necessary to regulate the tumor microenvironment during antitumor therapy. There are several strategies to regulate the tumor microenvironment as inhibiting tumor angiogenesis, reversing TAM phenotype, removing T cell immunosuppression, and so on. Nanotechnology holds great promise for improving antitumor efficacy of therapy, especially immunotherapy, through regulating the microenvironment. Unlike traditional cancer therapies, properly designed nanomaterials can trigger specific tumoricidal effects that improve immune cell access to major metastatic sites such as bone, lung, and lymph nodes, optimize antigen presentation, and induce long-lasting immune responses. Specifically, they can directly reverse the immune status of the primary tumor, harness the potential of peripheral immune cells, prevent the formation of a premetastatic niche, and inhibit tumor recurrence through postoperative immunotherapy. Nano-immunomodulators can not only eliminate the primary tumor effectively but also inhibit distal metastasis and prevent recurrence. In addition, nanomaterials can be used as multifunctional platforms to complement various immunotherapies of cancer.

This Special Issue on “Tumor Microenvironment Regulation and Antitumor Therapy Based on Nanoparticles” seeks high-quality work focusing on the latest advances of nanotechnology applied in cancer therapy. Topics include but are not limited to:

• The development of new nanomaterials for cancer therapy;
• The development of nanocarriers for personalized and precision medicine;
• The design of lipid/polymer/hybrid nanocarriers targeting for cancer therapy;
• The design of new macromolecules and derivatives for cancer therapy;
• Investigations of alternative therapeutic strategies involving nanocarriers for cancer therapy;
• Investigations on the translational aspects and scale-up of nanocarriers for cancer therapy.

Dr. Lianyan Wang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Functional Biomaterials is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• tumor
• microenvironment regulation
• nanoparticles
• antitumor therapy